Sonoma Pharmaceuticals, Inc. (SNOA) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
SNOA currently has 1.65M outstanding shares. with minimal authorized share overhang for future dilution. The company has significantly diluted shareholders by 63.7% over the past 2 years, indicating aggressive capital raising. Recent corporate actions include 1 stock split (positive for accessibility) and 1 reverse split (concerning signal).
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Apr 17, 2026 |
S-1 filing: Sonoma Pharmaceuticals, Inc. is filing an S-1 registration statement for a proposed offering of units, each consisting of one share of common stock (or a pre-funded warrant in lieu thereof) and one warrant to purchase one share of common stock. |
1.6M | 0 |
| Nov 04, 2025 |
10-Q filing | 1.6M shares outstanding |
1.6M | 0 |
| Aug 07, 2025 |
10-Q filing | 1.6M shares outstanding |
1.6M | 0 |
| Jun 17, 2025 |
10-K filing | 1.6M shares outstanding |
1.6M | 0 |
| Feb 05, 2025 |
10-Q filing | 1.5M shares outstanding |
1.5M | 0 |
| Nov 07, 2024 |
10-Q filing | 1.3M shares outstanding |
1.3M | 0 |
| Aug 29, 2024 |
Stock Split
8-K filing: Stock split 1-for-20 | Outstanding: 19,149,393 → 957,469 |
960K | 0 |
| Aug 08, 2024 |
10-Q filing | 19.1M shares outstanding |
19M | 0 |
| Jun 17, 2024 |
10-K filing | 18.8M shares outstanding |
19M | 0 |
| Feb 08, 2024 |
10-Q filing | 15.6M shares outstanding |
16M | 410K |
| Nov 13, 2023 |
10-Q filing | 13.7M shares outstanding |
14M | 2.3M |
| Nov 03, 2023 |
S-3 filing: Sonoma Pharmaceuticals files an S-3 form to offer and sell common stock, preferred stock, debt securities or warrants, either separately or in units, in one or more offerings up to a total aggregate offering price of $51,300,000. |
5.1M | 11M |
| Oct 13, 2023 |
S-1/A filing: Sonoma Pharmaceuticals, Inc. is offering up to 6,666,666 shares of common stock at an assumed price of $0.75 per share on a best efforts basis with Maxim Group LLC as the exclusive placement agent. |
5.1M | 11M |
| Sep 19, 2023 |
S-1 filing: Sonoma Pharmaceuticals, Inc. is offering up to 5,000,000 shares of common stock at an assumed price of $1.00 per share on a best efforts basis. |
5.1M | 9.2M |
| Aug 10, 2023 |
10-Q filing | 5.1M shares outstanding |
5.1M | 4.2M |
| Jun 21, 2023 |
10-K filing | 4.9M shares outstanding |
4.9M | 4.4M |
| Feb 14, 2023 |
10-Q filing | 4.6M shares outstanding |
4.6M | 4.7M |
| Nov 14, 2022 |
10-Q filing | 3.1M shares outstanding |
3.1M | 6.2M |
| Aug 11, 2022 |
10-Q filing | 3.1M shares outstanding |
3.1M | 6.2M |
| Jul 13, 2022 |
10-K filing | 3.1M shares outstanding |
3.1M | 6.2M |
| Feb 11, 2022 |
10-Q filing | 3.1M shares outstanding |
3.1M | 6.3M |
| Nov 15, 2021 |
10-Q filing | 3.1M shares outstanding |
3.1M | 6.3M |
| Aug 16, 2021 |
10-Q filing | 2.1M shares outstanding |
2.1M | 7.3M |
| Jul 14, 2021 |
10-K filing | 2.1M shares outstanding |
2.1M | 7.3M |
| Feb 16, 2021 |
10-Q filing | 2.1M shares outstanding |
2.1M | 7.3M |
| Dec 15, 2020 |
S-3/A filing: Sonoma Pharmaceuticals files an S-3/A form to offer common stock, preferred stock, and debt securities with an aggregate initial offering price not to exceed $63,425,000. |
2.1M | 7.2M |
| Nov 24, 2020 |
S-3 filing: Sonoma Pharmaceuticals files an S-3 form for a shelf offering of common stock, preferred stock, debt securities or warrants with an aggregate offering price not to exceed $63,425,000. |
2.1M | 0 |
| Nov 20, 2020 |
10-Q filing | 2.1M shares outstanding |
2.1M | 0 |
| Aug 14, 2020 |
10-Q filing | 1.8M shares outstanding |
1.8M | 0 |
| Jul 10, 2020 |
10-K filing | 1.8M shares outstanding |
1.8M | 0 |
| Feb 14, 2020 |
10-Q filing | 1.8M shares outstanding |
1.8M | 0 |